A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy

Trial Profile

A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Nitric oxide (Primary) ; Moxifloxacin
  • Indications Acne vulgaris
  • Focus Pharmacokinetics
  • Sponsors Novan Inc
  • Most Recent Events

    • 09 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 26 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 26 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top